The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 51-54

  Pannek, Jürgen ^a   Subong, Eric N P ^a   Jones, Kerrie A ^a   Marschke, Penny L S ^a   Epstein, Jonathan I ^a   Chan, Daniel W ^a   Carter, H Ballentine ^a   Luderer, Albert A ^b   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Dianon Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030480481     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00610-3     Document Type: Article

References (11)

1. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnik MI, Smalley SR, and Wasson JH: Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. J Urol 154: 2144-2148, 1995.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
3. Catalona WJ, Smith DS, Wolfert RL, Wang J, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum PSA to improve specifity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
4. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, and Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
5. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
6. Ellis WJ, Chetner MP, Preston SD, and Brawer MK: Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152: 1520-1525, 1994.
7. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate-specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1989.
8. Henricks WH, England BG, Giacherio DA, Oesterling JE, and Wojno KJ: Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J Urol 155: 369A, 1996.
9. Elgamal AA, Cornillie F, Van Poppel H, Van Dorpe JA, Gero E, Haberzettl C, McCabe R, and Baert LV: Free/total PSA ratio (F/T) as a single test for detection of significant T1c prostate cancer. J Urol 155: 369A, 1996.
10. Graefen M, Hammerer P, Henke P, Hilz H, Huland E, and Huland H: Percentage of free PSA does not correlate with pathological outcome. J Urol 155: 370A, 1996.
11. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch DW, and Catalona WJ: Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol 155: 415A, 1996.